Goodsurance
ES

Drug prices & Part D

Medicare Part D Rarely Covers the OTC Naloxone Nasal Spray. Medicaid Usually Does.

A new Government Accountability Office report finds that most Part D plans stopped covering the over-the-counter naloxone nasal spray after it no longer required a prescription, while Medicaid covers the same product at little or no cost to enrollees.

By the Goodsurance editorial teamNovember 16, 2026

Medicare Part D drug plans generally do not cover the over-the-counter naloxone nasal spray, the more user-friendly form of opioid overdose reversal medication, while Medicaid covers the same product at little or no cost to enrollees, the Government Accountability Office reported on November 9, 2026.

Naloxone nasal spray was reclassified as over-the-counter, which removed it from Part D's prescription-drug coverage framework. Part D covers only drugs that require a prescription, so once the spray went over the counter, most plans dropped it. Medicare enrollees who want the nasal spray typically pay out of pocket at a pharmacy. Part D plans continue to cover injectable naloxone, which still requires a prescription. The generic injectable form carried a median copay of 3 to 10 dollars, while brand-name injectable formulations required coinsurance of 25 to 35 percent, the GAO found.

Medicare Part D stopped covering the naloxone nasal spray when it went OTC. Medicaid still covers it. Here is what Medicare enrollees need to know.

Medicaid offered broader access. State Medicaid programs covered the OTC nasal spray for enrollees in 2024, with participants paying no copay or less than 5 dollars in the selected states the GAO reviewed.

The GAO also examined nalmefene, a longer-acting opioid reversal medication. Coverage of that drug was less common across both Medicare and Medicaid.

Medicare covers more than 65 million Americans, including many who are prescribed opioids for pain or who live with or care for someone at overdose risk. The nasal spray format is widely seen as easier to administer without medical training in an emergency. The report adds to a broader discussion about whether Part D coverage rules designed around prescription status keep pace when a drug moves over the counter.

In plain words

If you have Medicare, your Part D drug plan usually will not pay for the naloxone nasal spray. That is the medicine you spray into a person's nose to stop an opioid overdose. It used to need a prescription. Now you can buy it at the pharmacy without one, so Medicare Part D stopped covering it.

Medicare Part D will still help pay for a naloxone shot. The shot needs a prescription. The generic shot costs about 3 to 10 dollars with Medicare. The name-brand shot may cost 25 to 35 percent of the full price.

Medicaid does cover the nasal spray and charges little or nothing for it.

The nasal spray is easy to use in an emergency without special training. The shot is harder to use. A new report from the Government Accountability Office found this gap between Medicare and Medicaid.

If you have Medicare and want to have naloxone at home, you can still buy the nasal spray at a pharmacy without a prescription. You would just pay the full price yourself. Talk to your pharmacist about what your choices are.

Source: GAO
Read at the source →

More news

Other stories on what is moving in Medicare.

Drug prices & Part D

Biotech Industry Group Files Second Lawsuit to Block Medicare's GLOBE Drug Pricing Model

BIO and two California biotech groups sued CMS on November 6, arguing the program exceeds legal authority. A first challenge from PhRMA filed in October remains pending.

November 12, 2026

Drug prices & Part D

KFF: Medicare's 340B Drug Payment Cut Reduces Revenue for Safety-Net Hospitals While Raising It for For-Profit Ones

Now that the 2027 outpatient rule is final, a KFF analysis finds the 340B reimbursement cut falls hardest on hospitals that serve low-income patients, while for-profit hospitals see a net gain.

November 11, 2026

Drug prices & Part D

Medicare Drug Price Negotiation Rules Are Now Permanent, Federal Register Shows

The CMS-4215-F final rule, published today, converts the negotiation program from administrative guidance into binding federal regulation for every drug-price cycle starting in 2029, and requires Part D plans to cover negotiated-price drugs on their formularies.

November 9, 2026

Drug prices & Part D

Third Medicare Drug Negotiation Cycle Closes, Including Part B Doctor-Office Drugs for the First Time

The formal negotiation period for 15 drugs ended November 1; CMS must publish any agreed-upon maximum fair prices by November 30, including the first-ever negotiated prices for drugs given in doctors' offices.

November 1, 2026

Drug prices & Part D

Average Medicare Part D Stand-Alone Premium Projected to Rise 50 Percent for 2027, KFF Finds

A KFF analysis published today finds the average monthly premium for stand-alone Part D drug plans is on track to climb from 34 dollars to 51 dollars for 2027, with deductibles also rising sharply, for enrollees who do not switch plans before December 7.

October 30, 2026

Drug prices & Part D

Study: Medicare Drug Price Negotiations Cut Costs for Most Enrollees, but Not for Those Already Hitting the Annual Spending Limit

A research letter in Annals of Internal Medicine finds that patients on six of the first ten negotiated Part D drugs saw out-of-pocket costs fall 26 to 49 percent, while patients on the three highest-priced negotiated drugs saw no additional benefit because they were already reaching the annual cap.

October 24, 2026